Business Context and Reporting Period
The provided filing is Neuralstem, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, not Palisade Bio, Inc. The company develops human neural stem cell therapies and small-molecule compounds for central nervous system diseases. Its primary candidates were NSI-566 and NSI-189, all still in preclinical or clinical development with no commercial product revenue.
The filing reports quarterly data for the fourth quarter ended December 31, 2014, including revenue of $4,666, operating loss of $4.6 million, and net loss of $5.5 million.
Financial Condition and Results
| Metric | Fiscal 2014 | Fiscal 2013 | Change |
|---|---|---|---|
| Revenue | $18,833 | $110,000 | Down 83% |
| Operating expenses | $17.5 million | $12.6 million | Up 38% |
| Operating loss | $17.4 million | $12.5 million | Loss increased $4.9 million |
| Net loss | $22.6 million | $19.8 million | Loss increased $2.8 million |
| Basic and diluted loss per share | $0.26 | $0.27 | Improved per share due to higher share count |
| Net cash used in operations | $11.7 million | $10.6 million | Use increased $1.1 million |
| Cash and cash equivalents | $12.5 million | $16.8 million | Down $4.3 million |
| Short-term investments | $15.0 million | None | New balance-sheet category |
| Total liquidity | $27.5 million | $16.8 million | Up 63% |
| Long-term debt, net of discount | $8.8 million | $7.7 million | Up $1.1 million |
| Working capital | $24.2 million | $11.7 million | Up $12.5 million |
Revenue represented an immaterial portion of expenses, and the filing does not present a meaningful commercial operating margin. The company has accumulated losses of approximately $151.1 million since inception and has never generated revenue from product sales.
Research and development expense increased 14% to $8.1 million, primarily from higher payroll, project and laboratory costs, and clinical-trial activity. General and administrative expense increased 71% to $9.0 million, driven by approximately $2.0 million of additional stock-based compensation, higher legal and professional fees, consulting costs, and payroll.
Other expense was $5.2 million, including $3.1 million of warrant modification expense, $1.6 million of interest expense, a $446,000 loss on debt extinguishment, and a $334,000 change in the fair value of warrant obligations. A $250,000 litigation settlement payment partially offset these costs.
Material Changes Versus the Prior Comparable Period
- Revenue declined by approximately $91,000 because 2014 licensing revenue consisted only of ongoing annual fees, whereas 2013 included upfront license fees.
- Operating expenses increased $4.8 million as clinical and research activities expanded, while general and administrative spending rose substantially.
- Net loss increased from $19.8 million to $22.6 million, although loss per share decreased from $0.27 to $0.26 because weighted-average shares increased to 87.1 million from 72.3 million.
- The company raised approximately $19.5 million net from equity and warrant transactions and approximately $4.2 million net through a debt amendment.
- Investing cash outflows increased to $15.6 million, primarily because the company invested approximately $15.0 million in short-term certificates of deposit.
- Shares outstanding increased to 87.8 million at year-end from 77.9 million, excluding additional dilution from approximately 18.99 million outstanding options and 21.42 million outstanding warrants.
Guidance, Outlook, Risks and Unusual Items
- Management expected available cash and anticipated income to fund current activities through at least December 31, 2015, but stated that additional capital would be required for broader clinical development and operations.
- Management expected research and development spending to increase as NSI-566 and NSI-189 advanced into additional Phase II studies.
- Planned 2015 milestones included a controlled Phase II ALS trial, Phase II NSI-189 testing for major depressive disorder, a Phase Ib schizophrenia trial, advancement of the China stroke trial, and completion of enrollment for the chronic spinal cord injury trial.
- The amended debt facility has a variable interest rate with a 10% prime-rate floor. It required interest-only payments through September 2015, approximately $461,000 of monthly principal and interest payments from October 2015 through March 2017, and an approximately $2.1 million balloon payment in April 2017. Substantially all assets, including intellectual property, secure the debt.
- The company has recurring operating losses, negative operating cash flow, no product revenue, and dependence on equity offerings, debt, grants, licensing, and other external financing.
- Key risks include unsuccessful or delayed clinical trials, regulatory failure, manufacturing and supply dependence on third parties, intellectual-property disputes, competition, dilution, debt covenant or repayment risk, and inability to obtain financing.
- Patent litigation with StemCells, Inc. remained unresolved. A December 2014 bench trial addressed standing and inventorship, with post-trial briefs filed in January 2015; the outcome was uncertain.
- The company’s independent auditor issued an unqualified opinion and concluded that internal control over financial reporting was effective as of December 31, 2014.
Most Important Facts to Verify
- Confirm the filing identity: the supplied document is for Neuralstem, Inc., while the request metadata identifies Palisade Bio, Inc.
- Verify the company’s ability to fund operations beyond 2015 given annual losses, $11.7 million of 2014 operating cash use, and scheduled debt payments.
- Review the amended loan agreement, collateral package, covenants, interest-rate terms, and April 2017 balloon payment.
- Assess clinical-trial enrollment, safety, efficacy, regulatory status, and the evidentiary basis for management’s planned 2015 milestones.
- Evaluate dilution from outstanding options, warrants, equity financing capacity, and potential future capital raises.
- Review the unresolved StemCells patent litigation and any subsequent court ruling or settlement.
- Confirm that the reported liquidity includes $15.0 million of short-term certificates of deposit and assess their availability for operating needs.